RISK FACTORS FOR INFECTIOUS ADVERSE EVENTS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH VENETOCLAX COMBINATIONS: A RETROSPECTIVE SINGLE-CENTRE REAL-WORLD EXPERIENCE

RISK FACTORS FOR INFECTIOUS ADVERSE EVENTS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH VENETOCLAX COMBINATIONS: A RETROSPECTIVE SINGLE-CENTRE REAL-WORLD EXPERIENCE | Authorea try { document.documentElement.classList.add('js'); } catch (e) { } var _gaq = _gaq || []; _gaq.push(['_setAccount', 'G-8VDV14Y67G']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); Skip to main content Preprints Collections Wiley Open Research IET Open Research Ecological Society of Japan All Collections About About Authorea FAQs Contact Us Quick Search anywhere Search for preprint articles, keywords, etc. Search Search ADVANCED SEARCH SCROLL Cancer Reports This is a preprint and has not been peer reviewed. Data may be preliminary. 13 January 2025 V1 Latest version Share on RISK FACTORS FOR INFECTIOUS ADVERSE EVENTS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH VENETOCLAX COMBINATIONS: A RETROSPECTIVE SINGLE-CENTRE REAL-WORLD EXPERIENCE Authors : Olgu Erkin Çınar 0000-0003-1226-5797 [email protected] , Azade Kanat , Kerim Erer 0000-0001-8848-6495 , Rasim Şahin 0009-0003-9476-4844 , Esma Eryılmaz Eren , and Esra Yıldızhan Authors Info & Affiliations https://doi.org/10.22541/au.173677335.55374696/v1 Published Cancer Reports Version of record Peer review timeline 257 views 156 downloads Contents Abstract Supplementary Material Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract Background: Venetoclax-based (ven) combinations have become a standard of care for acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. However, the associated risk of infectious adverse events (IAEs) remains a significant clinical concern. Aims: This study aimed to evaluate the incidence, characteristics, and risk factors for IAEs in newly diagnosed AML patients treated with venetoclax combinations in a real-world setting. Methods and Results: We conducted a retrospective cohort study of AML patients treated with ven in combination with hypomethylating agents or low-dose cytarabine (LDAC), with analyses performed on a treatment cycle basis. Clinical and laboratory data, including IAE characteristics, duration of neutropenia, and concomitant medications, were collected, and grade ≥2 IAEs were included according to CTCAE v5.0 criteria. The cohort included 143 treatment cycles of 43 patients, with a median neutropenia duration of 13 days (5–35). A total of 34 (23.8%) grade ≥2 IAEs occurred, with an incidence of 1 per 121 patient-days. Multivariate analysis identified prolonged neutropenia (days, OR=1.037, p=0.005) and interacting concomitant medications (OR=9.99, p<0.001) as independent risk factors for IAEs. The rate of invasive fungal infections was as low as 3.5%, and the use of antifungal or antibacterial prophylaxis was not associated with a reduction in the rate of IAEs. Conclusion: IAEs remain a substantial risk in venetoclax-treated AML patients, particularly during prolonged neutropenia and with concomitant drug interactions. Optimizing venetoclax regimens and careful management of interacting medications may mitigate these risks. Supplementary Material File (manuscript.docx) Download 61.72 KB Information & Authors Information Version history V1 Version 1 13 January 2025 Peer review timeline Published Cancer Reports Version of Record 22 Dec 2025 Published Copyright This work is licensed under a Non Exclusive No Reuse License. Collection Cancer Reports Keywords acute myeloid leukemia infectious adverse events neutropenia venetoclax Authors Affiliations Olgu Erkin Çınar 0000-0003-1226-5797 [email protected] Kayseri Sehir Egitim ve Arastirma Hastanesi View all articles by this author Azade Kanat Kayseri Sehir Egitim ve Arastirma Hastanesi View all articles by this author Kerim Erer 0000-0001-8848-6495 Kayseri Sehir Egitim ve Arastirma Hastanesi View all articles by this author Rasim Şahin 0009-0003-9476-4844 Kayseri Sehir Egitim ve Arastirma Hastanesi View all articles by this author Esma Eryılmaz Eren Kayseri Sehir Egitim ve Arastirma Hastanesi View all articles by this author Esra Yıldızhan Kayseri Sehir Egitim ve Arastirma Hastanesi View all articles by this author Metrics & Citations Metrics Article Usage 257 views 156 downloads .FvxKWukQNSOunydq8rnd { width: 100px; } Citations Download citation Olgu Erkin Çınar, Azade Kanat, Kerim Erer, et al. RISK FACTORS FOR INFECTIOUS ADVERSE EVENTS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH VENETOCLAX COMBINATIONS: A RETROSPECTIVE SINGLE-CENTRE REAL-WORLD EXPERIENCE. Authorea . 13 January 2025. DOI: https://doi.org/10.22541/au.173677335.55374696/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu . Format Please select one from the list RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks Direct import Tips for downloading citations document.getElementById('citMgrHelpLink').addEventListener('click', function() { popupHelp(this.href); return false; }); $(".js__slcInclude").on("change", function(e){ if ($(this).val() == 'refworks') $('#direct').prop("checked", false); $('#direct').prop("disabled", ($(this).val() == 'refworks')); }); View Options View options PDF View PDF Figures Tables Media Share Share Share article link Copy Link Copied! Copying failed. Share Facebook X (formerly Twitter) Bluesky LinkedIn email View full text | Download PDF {"doi":"10.22541/au.173677335.55374696/v1","type":"Article"} Now Reading: Share Figures Tables Close figure viewer Back to article Figure title goes here Change zoom level Go to figure location within the article Download figure Toggle share panel Toggle share panel Share Toggle information panel Toggle information panel Go to previous graphic Go to next graphic Go to previous table Go to next table All figures All tables View all material View all material xrefBack.goTo xrefBack.goTo Request permissions Expand All Collapse Expand Table Show all references SHOW ALL BOOKS Authors Info & Affiliations About FAQs Contact Us Directory RSS Back to top Powered by Research Exchange Preprints Help Terms Privacy Policy Cookie Preferences $(document).ready(() => setTimeout(() => { let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" ")); $.get("/resource/lodash?t="+_bnt); },4000)); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'a00b4a28bd35df88',t:'MTc3OTYxNTExMA=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();